Market Newsdesk

HALIFAX, Nova Scotia, Nov. 17, 2020 (GLOBE NEWSWIRE) — Today, Oceana Canada released its fourth annual Fishery Audit which shows that Canada’s fisheries have declined since reporting began in 2017, and that a mere 26.5 per cent are now considered healthy. The number of healthy populations decreased by almost eight percentage points from 2017 to 2020, despite significant investments by the Canadian government in science, fisheries monitoring and management including a modernized Fisheries Act. To make matters worse, no comprehensive or meaningful rebuilding plans – crucial prerequisites to rebuilding collapsed populations – were released in 2020, and Fisheries and Oceans Canada only delivered on 14 per cent of its published priorities.

“There is an alarming gap growing between government commitment and action. There have been encouraging investments by the federal government in fisheries science and management in recent years. Unfortunately, this has not yet translated to action on the water. At this rate it will be 37 years before all critically depleted populations have a plan to rebuild them back to healthy levels,” says Josh Laughren, Executive Director, Oceana Canada. “Canadians and our coastal communities deserve well-managed fisheries for the future of their livelihoods and for food security.”

There have also been troubling decreases in crustaceans such as shrimp and crab and in small forage fish such as capelin, herring and mackerel that are prey for many commercially important fish, including cod and tuna. Crustaceans make up the economic backbone of Canada’s fisheries, and forage fish are essential to healthy marine ecosystems.

“Healthy fish populations are critical to healthy ecosystems and coastal communities. Our oceans are facing growing threats and greater uncertainty, putting the marine life we all depend upon at risk,” says Dr. Robert Rangeley, Science Director, Oceana Canada. “A lot is at stake, and it’s time for the government to take urgent action now to manage our oceans and fisheries sustainably. We can rebuild populations to provide more opportunities for coastal communities and make the Canadian seafood industry more resilient to growing threats such as climate change. As we look to rebuilding our economy post-pandemic, we must seize the opportunities that our ocean economy can provide.”

“Canada has an opportunity to think about the future we want and need as we set a path to recovery for our resource-rich nation. Failure to act now risks squandering the hundreds of millions of dollars of recent federal government investments to improve fisheries management. It would also mean losing out on the massive long-term potential of the original blue economy, wild fish, to support our planet,” says Rangeley.

In the year ahead, Oceana Canada is urging Fisheries and Oceans Canada to address its most critical gaps, including:

• Complete regulations to bring into force the new Fisheries Act provisions, including listing all major stocks in the critical zone that require rebuilding plans;
• Address inconsistencies in catch monitoring by implementing the national Fishery Monitoring Policy introduced in November 2019; and
• Develop and implement high-quality rebuilding plans that include targets and timelines to rebuild stocks back to healthy levels, as identified in 2020/21 work plans.

For more information, and to add your name to Oceana Canada’s urgent call to rebuild Canada’s fish populations, visit FisheryAudit.ca.

Oceana Canada was established as an independent charity in 2015 and is part of the largest international advocacy group dedicated solely to ocean conservation. Oceana Canada has successfully campaigned to end the shark fin trade, make rebuilding depleted fish populations the law, improve the way fisheries are managed and protect marine habitat. We work with civil society, academics, fishers, Indigenous
Peoples
and the federal government to return Canada’s formerly vibrant oceans to health and abundance. By restoring Canada’s oceans, we can strengthen our communities, reap greater economic and nutritional
benefits
and protect our future.

Contacts: Tammy Thorne, Oceana Canada, [email protected], 437-247-0954 and Kathleen Munro, Pilot PMR, [email protected], 902-789-3165. Media assets available here.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/938a3c40-a292-4477-82d5-74c62bc4377b

https://www.globenewswire.com/NewsRoom/AttachmentNg/8aeb5b95-a638-4b7c-80f4-b842a477e4dd

https://www.globenewswire.com/NewsRoom/AttachmentNg/0772ac87-8a62-4a73-87e6-a888adcbb460

https://www.globenewswire.com/NewsRoom/AttachmentNg/af181301-2439-4553-a996-a1d1b2126486

FREMONT, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Supercomputing2020 — Penguin Computing, a division of SMART Global Holdings, Inc. (NASDAQ: SGH) and leader in high-performance computing (HPC), artificial intelligence (AI), and enterprise data center solutions, today announced TrueHPC, an end-to-end, enterprise-supported HPC solution powered by Advanced Micro Devices, Inc. (AMD) and NVIDIA Mellanox HDR InfiniBand networking to deliver a workload-optimized HPC infrastructure, that scales to meet any workload, and accelerates time-to-innovation across HPC initiatives.

The HPC landscape has changed dramatically over the past two decades. New market entrants are using new strategies that push the boundaries of the discipline. At the same time, the underlying technology continues to evolve at an increasingly rapid pace. Designing the right HPC platform, that is specific to workloads and business objectives, and ensuring that the compute, storage, and networking subsystems are well-designed, individually, and function in a balanced manner, together, is critically important for the success of an HPC initiative. A poor design choice, at any point in the process, can negatively impact performance, reliability, availability, and serviceability, significantly reduce the value of the HPC investment, and reduce overall market competitiveness.

Penguin Com


p


uting TrueHPC
delivers a complete software, hardware and management platform built on compute-optimized hardware and Scyld^™ Clusterware orchestration software. This flexible and scalable solution accelerates time-to-innovation, speeds the adoption of rapidly changing technologies, reduces risk, and lowers total cost of ownership. TrueHPC leverages industry-leading technologies from AMD, NVIDIA, and others to enable a complete technology ecosystem in support of each unique workload. TrueHPC provides cluster management tools that allow customers to not only quickly and easily provision technical compute environments, but to efficiently monitor and manage them. TrueHPC can be implemented as a standalone solution or in combination with other Penguin Computing solutions and reference architectures for Data, AI, Analytics, and Cloud.

“With each new technological advance comes more choice. Building the right infrastructure and planning for the future of an HPC resource is challenging and complex for new HPC users and seasoned practitioners alike,” said Kevin Tubbs, Ph.D., and senior vice president, Strategic Solutions Group at Penguin Computing. “For more than two decades, Penguin Computing has been helping customers to design, build, and support custom HPC architectures. In collaboration with our partner NVIDIA, we’re continuing to meet the evolving technical requirements of the most demanding, data-driven workloads.”

“The HPC industry has evolved dramatically with the massive proliferation of data and corresponding increase in demand for more ways to access and power AI and HPC workloads,” said Gilad Shainer, senior vice president of networking at NVIDIA. “Penguin Computing’s choice to power TrueHPC with NVIDIA Mellanox InfiniBand networking will provide Penguin Computing users best-in-class performance and scale for building and deploying HPC systems that are future-proofed for tomorrow’s needs.”

With the launch of Penguin Computing’s four dedicated technology practices, TrueHPC is an integral part of the HPC Practice. The HPC Practice delivers targeted, modular, and complementary HPC architectures that improve performance and utility while lowering the barrier to adoption. Penguin Computing will shorten time to insight and discovery by removing the complexities involved in designing, deploying, supporting, and operating HPC infrastructure.

Penguin Computing TrueHPC will be available in mid-fiscal Q1 2021. For more information, please contact: [email protected]

Read more about Penguin Computing’s HPC Practice and the TrueHPCSolutionsBrief.

Follow Penguin Computing on Twitter @PenguinHPC and use our official hashtags #HPCeverywhere and #AIeverywhere to stay connected.

A
bout Penguin Computing

For 20 years, the Penguin Computing team of artificial intelligence (AI), engineering, and computer science experts has reimagined how startups, Fortune 500, government, and academic organizations solve complex technology challenges and achieve their organizational goals. Penguin Computing is focused on open platforms, including Open Compute Project (OCP) systems. We specialize in innovative high-performance computing (HPC), cloud, AI, and storage technologies coupled with leading-edge design, implementation, hosting and managed services including sys-admin and storage-as-a-service, all with highly rated customer support. More information at www.penguincomputing.com

TrueHPC and Scyld are trademarks owned by Penguin Computing, Inc.

All brands and trade names are trademarks or registered trademarks, and are the properties of their respective owners. 

Penguin Computing Media Contact

Karbo Communications
[email protected]

NEW YORK, NY, Nov. 17, 2020 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that the company estimates revenue to meet or exceed $27 million, representing sequential growth of at least 40%, for the quarter ended October 31, 2020.  

Enzo Biochem, Inc. also announced today that Fabian Blank and Peter Clemens have resigned from the company board of directors, effective immediately. Both board members were originally nominated by Harbert Discovery Fund, LP (Harbert), an investor in Enzo. The Nominating Committee for Enzo has already identified experienced Board candidates to fill the vacant seats and expects to announce their appointment in the near future.

“Enzo is projecting significant progress in our strategy to streamline operations to achieve profitability in fiscal 2021, which represents the culmination of several years of planning and execution,” said Dr. Elazar Rabbani, Ph.D., Enzo’s Chairman and Chief Executive Officer. “With our board and management team advancing our business strategy, we look to continue building new levels of momentum in this process in the months ahead.”

In 2020, Enzo announced several developments designed to advance its business operations, including receipt of FDA Emergency Use Authorization for the company’s GenFlex™ platform for COVID-19 testing, significant expansion of the Farmingdale, New York facility to meet rapidly expanding commercial demand for testing services, expansion of its School and Institutional Testing (SIT) program to support efforts by organizations to re-open safely during the COVID-19 pandemic, and launch of our direct-to-consumer testing service.  Most recently, the company launched its microplate reader for use with its ELISA and assay kits to simplify laboratory workflow.

“2020 has been a year of many significant accomplishments for Enzo that have strengthened our business operations and commercial opportunities, and we are pleased to see the results of these actions reflected in our revenue growth and expansion of our customer focus,” continued Dr. Rabbani.  “We have expanded our opportunities for success in all of our business sectors, including Molecular Diagnostics, Immunoassay, Immunohistochemistry, and Cytology, and the company is well positioned to maximize our potential for growth, investment, joint ventures, and partnerships in 2021.” 

About Enzo Biochem




 

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Forward-Looking Statements

Except for historical information, the matters discussed in this release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.

###

Contact:

For Enzo Biochem, Inc.

David Bench, CFO
212-583-0100
[email protected]

Media:

Marisa Monte        
Berry & Company Public Relations
212-253-8881
[email protected]

Investors:

Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
[email protected]

Steve Anreder
Anreder & Company
212-532-3232
[email protected]m

SUNNYVALE, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Kloudspot, Inc., makers of the first network-enabled and cloud-based Situational Awareness and Intelligence platform, today announced the Kloudspot QuickStart Bundle to provide a fast, affordable and easy way for any organization to re-open by monitoring key data metrics within a perimeter space such as a school or office.

“As we continue to battle the global pandemic, organizations are looking for solutions that enable their re-opening strategies,” said Guillermo Diaz, Jr., Kloudspot CEO. “We are working closely with our customers and partners to create spaces that are safe and flexible. The Kloudspot QuickStart Bundle is an easy to use, ‘in-a-box’ solution that combines the power of our platform with key connected IoT devices to monitor what’s happening in a space, and deliver real-time insights and actions to accelerate these re-opening strategies,” said Diaz.

The new bundle, with configurations and capacity options for small, medium and enterprise organizations, includes:

• Digital display monitors
• Kloudspot managed appliance
• Connected camera(s) for real-time facial recognition and PPE detection
• Connected thermal scanner(s) for ‘no-contact’ temperature readings
• Wi-Fi and Bluetooth receivers to monitor the perimeter space
• Subscription license for the Kloudspot Platform

“This new bundle is a very effective solution to accelerate the ‘Back to The Office’ strategy that many of our customers are promoting,” said Osamu Kikuchi, Head of Business Development at NEC Networks & Systems Integration Corporation (NESIC). “NEC is focused on leveraging technology to help organizations safely re-open and have a ‘single-pane-of-glass’ view of their data.”

Here’s How The Kloudspot QuickStart Bundle Works:

When people enter a space such as an office or school lobby, a camera detects PPE and a thermal scanner captures body temperature. Both are instantly displayed on a full size, digital monitor along with building capacity, and can trigger alerts such as when capacity limits are reached or there are PPE violations.

The Kloudspot Situational Awareness and Intelligence Platform ingests data from these connected sensors and applies artificial intelligence and machine learning to contextualize and analyze the data and deliver valuable business insights that trigger customer-defined actions.

“We set up the Kloudspot Quick-Start bundle in our office and the next day, we re-opened knowing our employees, tenants, customers and delivery people all felt safe and comfortable in the office,” said Harsha Pamulaparthi, President and CEO of Standav. “Everyone is greeted with a digital display that detects PPE, and a thermal scanner that provides no-contact temperature readings.”

Customers who buy the Kloudspot QuickStart bundle before December 31, 2020, will receive all of the required hardware free, as a way to enable as many organizations as possible to re-open. And for each purchase this year, Kloudspot will donate 1% to help local communities build digital capabilities.

Pricing and Availability: The Kloudspot QuickStart bundle is available now, and is subject to terms and conditions. The free hardware offer is valid on purchases made by December 31, 2020. Contact Kloudspot, or a participating Kloudspot reseller/partner for details.

About Kloudspot:

Founded in 2016, the Kloudspot Situational Awareness and Intelligence Platform enables the creation of intelligent spaces and engagement systems using Wi-Fi and sensor networks. Organizations can leverage automated, AI driven, actionable insights to deliver compelling digital engagements and ensure safety measures for constituents. Kloudspot partners develop solutions that enhance health and safety, lifestyle, and workspace/education experiences for their customers.

For more information, or to request a demo or find a partner, please visit Kloudspot, Inc., Follow Kloudspot on Twitter, or connect on Facebook or LinkedIn.

Contact:

Connect Marketing
Holly Hagerman
(801) 373-7888
[email protected]

Dr. Rakesh Jetly Appointed Chief Medical Officer

Company Announces International Expansion of Clinical Trial Sites for Phase 2A Study into Psychedelic Treatments for PTSD in Veterans

VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced the appointment of Dr. Rakesh Jetly as Chief Medical Officer. The Company is also announcing a significant international expansion of its Phase 2A clinical research into the efficacy of psilocybin and psychedelic-assisted psychotherapy to treat Veterans, EMS, and First Responders with a PTSD indication. 

Dr. Rakesh Jetly Appointed as Chief Medical Officer

In an effort to build a team of diverse experts who understand the potential of psychedelic-based treatments and the mental health struggles of veterans and frontline service members, Mydecine has appointed Dr. Rakesh Jetly, OMM, CD, MD, FRCPC to serve as Chief Medical Officer. Dr. Jetly brings to Mydecine a wealth of experience not only as a medical advocate for the use of psychedelic-assisted psychotherapy, but also as a prominent voice in the fight against post-traumatic stress disorder (PTSD) and other mental health issues facing vulnerable populations like veterans and first responders. Dr. Jetly currently serves as Academic Chair of Military Mental Health at The Royal’s Institute of Mental Health Research, and as an associate professor of psychiatry at Dalhousie University (Halifax), and the University of Ottawa. In 2015, he was appointed, “The Canadian Forces Brigadier Jonathan C. Meakins, CBE, RCAMC Chair in Military Mental Health.” He has published numerous articles in professional journals and presents nationally and internationally on such topics as PTSD and operational psychiatry.

“Over the years as a general duty medical officer and then a uniformed psychiatrist I have become acutely aware of the importance and challenge of transition from active duty to veteran,” said Dr. Jetly. “I am now facing the same process and am thankful that my transition will allow me to continue to work in the space that confronts the challenge of PTSD. Having deployed in missions in Rwanda and the Middle East, and witnessing first hand intense trauma of combat during deployments in Afghanistan, I am keenly aware of the suffering of the incredible men and women that sacrifice so much in our Armed Forces and suffer from operational stress injuries.”

As Chief Medical Officer, Dr. Jetly will lead Mydecine’s scientific research and clinical trials related to psychedelic-assisted psychotherapy using psilocybin to treat PTSD. Dr. Jetly will also keep Mydecine abreast of new scientific research related to psychedelics, and offer strategic guidance as it relates to all aspects of patient care, medical safety, medical compliance and the administration of psychedelics. Additionally, Dr. Jetly will also engage medical professionals and veterans’ organizations through outreach and educational offerings regarding the use of psychedelics as medicine. 

Dr. Jetly added, “upon following the favorable clinical data and developments in the psychedelic space, I was struck by the commitment and enthusiasm of the Mydecine team to bring forth mental health solutions, specifically among the veteran population. I am extremely excited to join Mydecine’s leadership team and look forward to the opportunity to continue to educate and advance the global conversation on the promise of psychedelics in dealing with things like treatment-resistant PTSD. I am particularly excited to leverage the relationships that I have within NATO and beyond to bring some of the best clinicians and scientists to help tackle the deployment related mental health injuries.”

“We welcome Dr. Jetly to our senior leadership team as he makes his transition back into civilian life. We expect his impeccable reputation, medical knowledge and relationships with key veterans’ organizations will be valuable assets for Mydecine,” said Joshua Bartch, CEO of Mydecine. “In our research, we are targeting some of the most debilitating conditions and treatment-resistant syndromes facing the veteran’s population like chronic PTSD, depression and extreme anxiety. With Dr. Jetly’s leadership and guidance we believe we will be able to prove the long-term importance and efficacy of these compounds and treatments.”

New International Sites for Phase 2A Clinical Trials into Psychedelic Therapy for PTSD in Veterans

Mydecine announced the international expansion of its Phase 2A clinical trials of psilocybin-assisted psychotherapy to treat chronic PTSD in veterans and EMS personnel. The research will take place at Leiden University Medical Centre in the Netherlands; the University of Western Ontario; and the University of Alberta, with other clinical sites on the horizon in the USA, Europe, and Australia. 

The purpose of these trials will be to explore how the brain responds to psychedelics and develop a better understanding of the biological underpinnings created by the psychedelic experience. Through these trials, Mydecine hopes to establish the safety and efficacy of psychedelic administered psychotherapy in a safe and supervised setting, utilizing strict protocols approved by research ethics boards and build upon the body of work that has led to psilocybin-assisted psychotherapy to receive “breakthrough” status by the FDA. 

“The choice of working with veterans as our first subjects in our clinical trials was made for a variety of reasons. Along with my experience, and that of our Scientific Advisory Board, we have devoted our professional lives to the treatment of soldiers and veterans suffering from a variety of mental health conditions including PTSD,” said Dr. Jetly. “Those who have treated veterans and connected research in the same group have come to the realization that, although many evidence-based treatments exist for PTSD, they are built largely on the ‘fear-based model,’ and sadly a significant proportion of those suffering do not respond positively. In fact, veterans tend to respond less often to the evidence-based therapies compared to other types of trauma.”

Psychedelic-assisted psychotherapy also allows for exploration of an important growing concept that appears to be particularly relevant in military populations known as Moral Injury. Moral Injury describes persistent psychological difficulties that include guilt, shame and anger that may become amplified when one perceives moral transgression of highly held values. It is hoped that after the psychedelic experience the internal reflection may allow therapists to influence these difficult-to-treat emotions.

Dr. Jetly added, “when we review the literature, we see psychedelics and psychotherapy being used effectively to treat a variety of conditions from depression and PTSD to chronic pain and addictions. When a treatment works in such varied conditions, we must wonder about a common underlying mechanism. We hope to study the brain and body via neuroimaging, electrophysiology and blood-based biomarkers in order to identify the key characteristics that lead to patients fundamentally changing to accept psychotherapy that they would not otherwise be receptive to.”

In addition to the sites in the Netherlands, Ontario and Alberta, Mydecine is exploring additional trial sites across North America including Ottawa, Los Angeles, New York and Boston. 

About Mydecine Innovations Group 
Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada. Mydecine’s portfolio companies Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ position the company at the forefront of disruptive modern medicine.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

Mydecine Innovations Group Media Contacts

Anne Donohoe / Nick Opich
KCSA Strategic Communications
[email protected] / [email protected] 
212-896-1265 / 212-896-1206

On behalf of the Board of Directors:

Joshua Bartch, Chief Executive Officer
[email protected]

Corp Communication:

Charles Lee, Investor Relations
[email protected]
+1 720-277-9879

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at


www.sedar.com


or visit the Company’s website at


www.mydecine.com


.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

• Partnership further extends the availability of EDAP’s High Intensity Focused Ultrasound (HIFU) technology to one of the largest markets in Europe

• Complementary to AB Medica’s extensive product portfolio which includes robotic surgery solutions as well as ExactVu

LYON, France, November 17, 2020 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today that the company has signed an exclusive distribution agreement with AB Medica, a leading distribution of medical technologies across Italy.

Marc Oczachowski, Chairman and Chief Executive Officer of EDAP, commented: “We are very pleased to partner with AB Medica, a widely recognized leader in Italy for the distribution of cutting-edge medical technologies. This is clearly a step forward for EDAP in its HIFU adoption and commercialization program in Europe, as Italy is the fourth largest market for medical devices. Notably, AB Medica had already been distributing ExactVu, so they are familiar with our product line and have been able to incorporate Focal One very quickly. AB Medica also has extensive experience in the distribution of robotic prostate surgery solutions, so they are the perfect fit for us. We look forward to a very successful partnership.”

Filippo Pacinotti, Business Director of AB Medica, stated: “We are thrilled to have entered into this distribution agreement with EDAP, which is already a highly recognized name in Italy. This partnership will not only see us strengthen our presence in high definition ultrasound with ExactVu, but will also give us the opportunity to become a reference point in lithotripsy and HIFU, rounding out what will be an outstanding urology product portfolio. We are confident that we will meet EDAP’s expectations, and we are eager to start this new adventure with great enthusiasm.”

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.  EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

About AB Medica

Founded in 1984 by Aldo Cerruti, still the company’s President, ab medica is now Italy’s leading company in the production and distribution of medical technologies, as well as a reference point for robotic surgery and technological innovation in healthcare. Excellence, quality, technological innovation and competitiveness all rotate around our single mission which is to put people and their wellbeing at the centre of every one of our activities. Thanks to its synergistic collaboration with other companies in the holding, ab medica has now acquired a leading role in the field of Research & Development, with important projects and solutions in sectors such as genomics, tissue engineering and stem cells, together with intensified relations with universities, research centres and international scientific laboratories. For more information on the company, please visit their website www.abmedica.it/en/.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company’s filings with the Securities and Exchange Commission and in particular, in the sections “Cautionary Statement on Forward-Looking Information” and “Risk Factors” in the Company’s Annual Report on Form 20-F.

Company Contact

Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
[email protected]

Investor Contact

Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
[email protected]

Press Release

Nokia Deepfield identifies 2020 network traffic, internet consumption trends in new intelligence report

• Implications for service providers and internet service delivery chain with significant growth in video streaming, gaming, video conferencing and DDoS
   
• Data recorded by service providers across Europe and North America from February to September shows 30% increase in video subscribers, 23% increase in VPN end-points in the U.S, 40-50% increase in DDoS traffic

17 November 2020

Espoo, Finland –
Nokia Deepfield has today released its Network Intelligence Report, which examines service provider network traffic and consumption trends in 2020, revealing the networks were made to withstand the internet’s rollercoaster year. The report examines overall changes in internet traffic patterns in the last decade and in 2020, focusing on key application areas such as video streaming, video conferencing, gaming and Distributed Denials of Service (DDoS) security.

As COVID-19 lockdown measures were implemented in March-April 2020, consumer and business behavioral changes transformed the internet’s shape and how people use it virtually overnight. Many networks experienced a year’s worth of traffic growth (30-50%) in just a few weeks. By September, traffic had stabilized at 20-30% above pre-pandemic levels, with further seasonal growth to come. From February to September, there was a 30% increase in video subscribers, a 23% increase in VPN end-points in the U.S., and a 40-50% increase in DDoS traffic.

In the decade prior to the pandemic, the internet had already seen massive and transformative changes – both in service provider networks and in the evolved internet architectures for cloud content delivery. Investment during this time meant the networks were in good shape and mostly ready for COVID-19 when it arrived.

Manish Gulyani, General Manager and Head of Nokia Deepfield, said: “Never has so much demand been put on the networks so suddenly, or so unpredictably. With networks providing the underlying connectivity fabric for business and society to function as we shelter-in-place, there is a greater need than ever for holistic, multi-dimensional insights across networks, services, applications and end users. Nokia Deepfield’s software applications have allowed service providers to understand activity in their networks in these critical times. The data and insights we’ve drawn on for this report also show how continuity of service can be ensured to create value for their customers.” 

After monitoring network traffic over an eight-month period, Nokia Deepfield identified five key takeaways for service providers to use in planning future network capacity and value-added services for their subscribers:

• #1 The networks were made for this. While the networks held up during the biggest demand peaks, data from September 2020 indicates that traffic levels remain elevated even as lockdowns are eased; meaning, service providers will need to continue to engineer headroom into the networks for future eventualities.
   
• #2 Content delivery chains are evolving. Demand for streaming video, low-latency cloud gaming and video conferencing, and fast access to cloud applications and services, all placed unprecedented pressure on the internet service delivery chain. Just as Content Delivery Networks (CDNs) grew in the past decade, it’s expected the same will happen with edge/far edge cloud in the next decade – bringing content and compute closer to end users.
   
• #3 Residential broadband networks have become critical infrastructure. With increased needs (upstream traffic was up more than 30%), accelerating rollout of new technologies – such as 5G and next-gen FTTH – will go a long way towards improving access and connectivity in rural, remote and underserved areas. Better analytical insights enable service providers to keep innovating and delivering flawless service and loyalty-building customer experiences.
   
• #4 Deep insight into network traffic is essential. While the COVID-19 era may prove exceptional in many ways, the likelihood is that it has only accelerated trends in content consumption, production and delivery that were already underway. Service providers must be able to have real-time, detailed network insights at their disposal – fully correlated with internet traffic insights – to get a holistic perspective on their network, services and consumption.
   
• #5 Security has never been more important. During the pandemic, DDoS traffic increased between 40-50%. As broadband connectivity is now largely an essential service, protecting network infrastructure and services becomes critical. Agile and cost-effective DDoS detection and automated mitigation are becoming paramount mechanisms to protect service provider infrastructures and services.

The report’s data was gathered from network service providers across Europe and North America from February to September 2020 using the Nokia Deepfield portfolio of network insights and security applications, which use big data analytics to monitor, analyze and understand network traffic and services.  

Resources

• Report:
  
  Network Intelligence Report: Networks in 2020
  
  
• Webpage:
  
  Nokia Deepfield
  
  
• Webpage:
  
  Nokia Deepfield Genome
  
  

About Nokia Deepfield

Nokia Deepfield is an expert in providing a new generation of big data-driven network intelligence and analytics technology that can help service providers obtain real-time, granular, accurate and multidimensional details about the network, services, network flows, and usage patterns. Our Deepfield Genome™ continually monitors the internet traffic globally and empowers service providers with service- and security-related insights which they can correlate with real-time insights from their networks. Using the Nokia Deepfield portfolio of applications, service providers can plan, optimize and ensure their internet infrastructures have enough capacity and ability to deliver all services, with high performance, security and automation even under the increased traffic demand.

About Nokia

We create the technology to connect the world. Only Nokia offers a comprehensive portfolio of network equipment, software, services and licensing opportunities across the globe. With our commitment to innovation, driven by the award-winning Nokia Bell Labs, we are a leader in the development and deployment of 5G networks.

Our communications service provider customers support more than 6.4 billion subscriptions with our radio networks, and our enterprise customers have deployed over 1,300 industrial networks worldwide. Adhering to the highest ethical standards, we transform how people live, work and communicate. For our latest updates, please visit us online www.nokia.com and follow us on Twitter @nokia.

Media Inquiries:

Nokia
Communications
Phone: +358 10 448 4900
Email: [email protected]